Latest news
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui - fiercebiotech.comfiercebiotech.com · Thu, 06 Aug 2026 12:27:37 GMTUpdated: Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3 - Endpoints NewsEndpoints News · Thu, 06 Aug 2026 06:56:00 GMTJiangsu Hengrui discloses 8.9% Kailera Therapeutics (KLRA) stake in ownership filing - Stock TitanStock Titan · Wed, 05 Aug 2026 10:05:24 GMTHengrui Eyes Fresh NDA For Mounjaro Rival After Second Phase III Diabetes Win - insights.citeline.cominsights.citeline.com · Wed, 05 Aug 2026 08:11:52 GMTHengrui Pharmaceuticals Gets China Nod for Lung Cancer Combo Trials - MoomooMoomoo · Wed, 05 Aug 2026 03:25:12 GMTHengrui wins China approval for first domestically developed basal insulin analog - AllSciAllSci · Fri, 31 Jul 2026 12:56:19 GMTHow 2 FDA citations complicate Hengrui, Elevar’s push for liver cancer combo approval - Fierce PharmaFierce Pharma · Tue, 28 Jul 2026 07:00:00 GMTJiangsu Hengrui Pharmaceuticals Gets China Nod for Hypertension Drug Trial - MoomooMoomoo · Tue, 28 Jul 2026 01:45:39 GMT